NextGen Class of 2024
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss BioSpace’s tenth annual NextGen list of the hottest new life sciences companies.
The therapeutic targets of many of our top startups are also reflected in recent big biopharma acquisitions and partnerships.
ALL NEXTGEN CLASSES
